×

Biotech and Pharmaceuticals Pharmaceuticals

  • Drugmaker GlaxoSmithKline said the Food and Drug Administration approved it late Friday. Studies paid for by Glaxo found it prevents shingles in about 90 percent of people. The U.S. Centers for Disease Control and Prevention, though, recommends vaccination for those 60 or older, partly because it loses effectiveness over time.

  • Oct 20- Drugmaker Merck& Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday. The aim is "to better support changes in our business in the United States," she said. Merck's stock was little changed in midday trading on the New York Stock...

  • Oct 20- Drugmaker Merck& Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday. The aim is "to better support changes in our business in the United States," Gillespie said. Merck said none of the jobs being eliminated are being moved outside of...

  • Oct 20- The head of the U.S. Food and Drug Administration said the agency was working with several pharmaceutical and medical device companies in Puerto Rico to prevent shortages of medical products in the United States as it joins a massive effort to help rebuild the island that was ravaged by Hurricane Maria. FDA Commissioner Scott Gottlieb said the agency...

  • San Diego- based Imprimis' therapy will cost 99 cents for a month's supply, with refills starting at $79 a month and the company will start selling prescriptions on Nov. 1, Imprimis' Chief Executive Mark Baum told Reuters. "Cyclosporine is off-patent, happens to be inexpensive and we buy it from FDA- registered manufacturers," Baum said. The company makes a $1 copycat of...

  • San Diego- based Imprimis' therapy will cost 99 cents for a month's supply, with refills starting at $79 a month and the company will start selling prescriptions on Nov. 1, Imprimis' Chief Executive Mark Baum told Reuters. "Cyclosporine is off-patent, happens to be inexpensive and we buy it from FDA- registered manufacturers," Baum said. The company makes a $1 copycat of...

  • Mark Alles

    Celgene said Thursday that it won't initiate a phase 3 trial for a Crohn's disease drug.

  • San Diego- based Imprimis' therapy will cost 99 cents for a month's supply, with refills starting at $79 a month and the company will start selling prescriptions on Nov. 1, Imprimis' Chief Executive Mark Baum told Reuters. "Cyclosporine is off-patent, happens to be inexpensive and we buy it from FDA- registered manufacturers," Baum said. The company makes a $1 copycat of...

  • The drugmaker, which had a market cap of $29.30 million at the close of trade on Wednesday, said it would offer a compound formulation of cyclosporine, the off-patent version of Restasis. It will cost 99 cents for a month's supply and refills start at $79 a month. Allergan recently stirred controversy after striking a deal with a Native American tribe that would...

  • The headquarters of Roche AG in Basel, Switzerland.

    Roche's third-quarter sales rose 6 percent to 13.1 billion Swiss francs ($13.37 billion).

  • *New wave of firms pioneer discovered-in- China medicines. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca. "China is in vogue because of...

  • ZURICH, Oct 19- Roche's third-quarter sales rose 6 percent, the world's biggest cancer drug maker said on Thursday, beating analyst forecasts thanks to better-than-expected revenue from its new multiple sclerosis medicine Ocrevus. Third-quarter sales were 13.1 billion Swiss francs, compared to the 13.04 billion francs average estimate by analysts in a...

  • Cramer Remix: Johnson & Johnson is out of battleground territory

    Jim Cramer explains why the bulls are right and the stock of Johnson & Johnson is worth owning.

  • 'Washington shenanigans' a great buying opportunity

    Jim Cramer finds great buys pegged to the Trump administration's actions, but few that are tied to tax reform.

  • BioMarin is 'close as can get' to a hemophilia cure, CEO says

    Jim Cramer caught up with JJ Bienaime, the chairman and CEO of BioMarin, who spoke to his company's promising pipeline of drugs.

  • Jim Cramer on "Mad Money."

    Jim Cramer explains why the bulls are right and the stock of Johnson & Johnson is worth owning.

  • Cramer sees great buying opportunities in 'Washington's shenanigans'

    Jim Cramer finds great buys pegged to the Trump administration's actions, but few that are tied to tax reform.

  • The Food and Drug Administration allowed sales of the treatment from Kite Pharma on Wednesday. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead...

  • Donald Trump

    Jim Cramer finds great buys pegged to the Trump administration's actions, but few that are tied to tax reform.

  • Oxycodone

    How Trump's plan to declare the opioid crisis a national emergency could put a huge dent in drug industry profits, says Jake Novak.